Form 8-K - Current report:
SEC Accession No. 0001104659-21-134062
Filing Date
2021-11-04
Accepted
2021-11-04 08:35:42
Documents
14
Period of Report
2021-11-04
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2130971d2_8k.htm   iXBRL 8-K 26783
2 EXHIBIT 99.1 tm2130971d2_ex99-1.htm EX-99.1 16545
6 GRAPHIC tm2130971d2_ex99-1img001.jpg GRAPHIC 4177
  Complete submission text file 0001104659-21-134062.txt   231916

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vyne-20211104.xsd EX-101.SCH 3216
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vyne-20211104_lab.xml EX-101.LAB 34594
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vyne-20211104_pre.xml EX-101.PRE 22731
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2130971d2_8k_htm.xml XML 3712
Mailing Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807
Business Address 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 211378211
SIC: 2834 Pharmaceutical Preparations